Role of mast cell tryptase in renal interstitial fibrosis.
Renal interstitial fibrosis is characterized by increased proliferation of fibroblasts and excessive accumulation of extracellular matrix. Mast cell tryptase has been implicated in the development of tissue fibrosis in skin and lungs. However, the significance of mast cell tryptase in human renal diseases has not been investigated. The potential role of mast cell-derived tryptase in the development of renal fibrosis was studied using immunohistochemical techniques and cultured human renal fibroblast cell lines. Semiquantitative immunostaining analysis of samples from 70 patients with several renal diseases, including IgA glomerulonephritis (GN) (n = 30), non-IgA GN (n = 5), membranous GN (n = 5), focal segmental glomerulosclerosis (n = 4), minor glomerular abnormalities (n = 5), lupus nephritis (n = 3), and acute or chronic tubulointerstitial nephritis (n = 18), revealed that the degree of renal interstitial fibrosis was well correlated with the number of infiltrating tryptase-positive mast cells (P < 0.01). Mast cells could not be detected in damaged glomeruli in any form of renal disease. [(3)H]Thymidine uptake experiments demonstrated that DNA synthesis by cultured renal fibroblasts was increased with the concentration of tryptase (0.5 to 5 nM) coincubated with heparin and was suppressed by coincubation with the protease inhibitors leupeptin and benzamidine hydrochloride. Tryptase alone also increased DNA synthesis by fibroblasts but exhibited less effectiveness, compared with the combination of tryptase and heparin. Conversely, heparin alone suppressed DNA synthesis by fibroblasts. Metabolic [(35)S]methionine-labeling experiments with cultured renal fibroblasts indicated that tryptase increased the synthesis of fibronectin and collagen type I, in a dose-dependent manner. These findings suggest that mast cell tryptase plays a role in the proliferation and extracellular matrix protein production of renal interstitial fibroblasts and thus contributes to the development of renal interstitial fibrosis.
Kondo
Shuji
S
Department of Pediatrics, School of Medicine, University of Tokushima, Tokushima, Japan.
Kagami
Shoji
S
Department of Pediatrics, School of Medicine, University of Tokushima, Tokushima, Japan.
Kido
Hiroshi
H
Institute for Enzyme Research, University of Tokushima, Tokushima, Japan.
Strutz
Frank
F
Department of Nephrology and Rheumatology, Georg August University Medical Center, Göttingen, Germany.
Müller
Gerhard A
GA
Department of Nephrology and Rheumatology, Georg August University Medical Center, Göttingen, Germany.
Kuroda
Yasuhiro
Y
Department of Pediatrics, School of Medicine, University of Tokushima, Tokushima, Japan.
D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003094:Collagen / Q000235:genetics; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D005355:Fibrosis; D006801:Humans; D007668:Kidney / Q000166:cytology / Q000473:pathology; D007674:Kidney Diseases / Q000201:enzymology / Q000503:physiopathology*; D008407:Mast Cells / Q000201:enzymology*; D008934:Mitogens / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012697:Serine Endopeptidases / Q000494:pharmacology / Q000502:physiology*; D053802:Tryptases
D016326:Extracellular Matrix Proteins; D008934:Mitogens; D012333:RNA, Messenger; D003094:Collagen; D012697:Serine Endopeptidases; D053802:Tryptases